Uncategorized
Rhopressa meets primary endpoint in Rocket 2 trial
Rhopressa showed non-inferiority to timolol in glaucoma patients with baseline IOP below 25 mm Hg in a phase 3 clinical trial, Aerie Pharmaceuticals announced.Vicente Anido Jr., PhD, CEO of Aerie, reviewed results of the Rocket 2 trial during a company-sponsored conference call.